The global carrier screening market size is expected to reach USD 3.64 billion by 2030, according to a new study. The report “Carrier Screening Market Share, Size, Trends, Industry Analysis Report, By Type (Expanded Carrier Screening, Targeted Disease Carrier Screening); By Medical Condition; By Technology; By End-User; By Regions; Segment Forecast, 2022 - 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The well-established healthcare infrastructure and the rise in innovative product introductions are driving the expansion of the industry. Many countries concentrate their efforts on developing enhanced medical infrastructure that includes enhanced treatment techniques.
Furthermore, developed-country nations have modern healthcare infrastructure integrated with various transmission methods, pushing the rise and need for these techniques throughout such countries. Many people wish to discover if their genetic or inherited disorders might be transmitted to their offerings. As a result, these factors are expected to open up promising growth opportunities for companies in the overall industry during the forecasted period.
Additionally, the increasing prevalence of fetal chromosomal abnormalities boosts industry growth. According to the WHO, congenital abnormalities are major causes of fetal and infant mortality, chronic illness, and disabilities. Every year, an estimated 295 000 newborns nationwide die within 28 days of birth due to congenital abnormalities. Thus, the rising prevalence of fetal abnormalities, increasing product launches, and established healthcare infrastructure propel the industry growth during the forecast period.
Based on the type, the expanded segment accounted for the leading share in the industry in 2021. Customized panel testing and predesigned panel testing are the extended segment components. Due to advancements in DNA sequencing, polymerase chain reaction, metabolomics, and other technologies, the expanded sector accounted for most of the global market share in 2021.
Market players such as Abbott Laboratories, 23Andme Inc., Autogenomics Inc., Danaher Corporation, Fulgent Genetics Inc., Eurofins Scientific, Illumina Inc., Luminex Corporation, Invitae Corporation, MedGenome, Natera Inc., Myriad Genetics, Opko Health, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Roche AG, Sequenom Inc., and True Health. are some key players operating in the global market.
The well-established healthcare infrastructure and the rise in innovative product introductions are driving the expansion of the industry. Many countries concentrate their efforts on developing enhanced medical infrastructure that includes enhanced treatment techniques.
Furthermore, developed-country nations have modern healthcare infrastructure integrated with various transmission methods, pushing the rise and need for these techniques throughout such countries. Many people wish to discover if their genetic or inherited disorders might be transmitted to their offerings. As a result, these factors are expected to open up promising growth opportunities for companies in the overall industry during the forecasted period.
Additionally, the increasing prevalence of fetal chromosomal abnormalities boosts industry growth. According to the WHO, congenital abnormalities are major causes of fetal and infant mortality, chronic illness, and disabilities. Every year, an estimated 295 000 newborns nationwide die within 28 days of birth due to congenital abnormalities. Thus, the rising prevalence of fetal abnormalities, increasing product launches, and established healthcare infrastructure propel the industry growth during the forecast period.
Based on the type, the expanded segment accounted for the leading share in the industry in 2021. Customized panel testing and predesigned panel testing are the extended segment components. Due to advancements in DNA sequencing, polymerase chain reaction, metabolomics, and other technologies, the expanded sector accounted for most of the global market share in 2021.
Market players such as Abbott Laboratories, 23Andme Inc., Autogenomics Inc., Danaher Corporation, Fulgent Genetics Inc., Eurofins Scientific, Illumina Inc., Luminex Corporation, Invitae Corporation, MedGenome, Natera Inc., Myriad Genetics, Opko Health, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Roche AG, Sequenom Inc., and True Health. are some key players operating in the global market.
The publisher has segmented the carrier screening market report based on type, medical condition, technology, end-user, and region:
Carrier Screening, Type Outlook
- Expanded
- Customized Panel Testing
- Predesigned Panel Testing
- Targeted Disease
Carrier Screening, Medical Condition Outlook
- Pulmonary Conditions
- Hematological Conditions
- Neurological Conditions
- Other Conditions
Carrier Screening, Technology Outlook
- DNA Sequencing
- Polymerase Chain Reaction
- Microarrays
- Other Technologies
Carrier Screening, End-User Outlook
- Hospitals
- Reference Laboratories
- Physician Offices & Clinics
- Other End Users
Carrier Screening, Regional Outlook
- North America
- U.S.
- Canada
- Europe
- France
- Germany
- UK
- Italy
- Netherlands
- Spain
- Austria
- Asia Pacific
- China
- India
- Japan
- Malaysia
- South Korea
- Indonesia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Frequently Asked Questions about the Global Carrier Screening Market
What is the estimated value of the Global Carrier Screening Market?
What is the growth rate of the Global Carrier Screening Market?
What is the forecasted size of the Global Carrier Screening Market?
Who are the key companies in the Global Carrier Screening Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 114 |
| Published | April 2022 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 1.41 billion |
| Forecasted Market Value ( USD | $ 3.64 billion |
| Compound Annual Growth Rate | 11.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Global Carrier Screening Market Insights
5. Global Carrier Screening Market, by Medical Condition
6. Global Carrier Screening Market, by Type
7. Global Carrier Screening Market, by Technology
8. Global Carrier Screening Market, by End-User
9. Global Carrier Screening Market, by Geography
10. Competitive Landscape
11. Company Profiles
Companies Mentioned
- 23Andme Inc.
- Abbott Laboratories
- Autogenomics Inc.
- Danaher Corporation
- Eurofins Scientific
- Fulgent Genetics Inc.
- Illumina Inc.
- Invitae Corporation
- Luminex Corporation
- MedGenome
- Myriad Genetics
- Natera Inc.
- Opko Health
- Quest Diagnostics Incorporated
- Roche AG
- Sequenom Inc.
- Thermo Fisher Scientific Inc.
- True Health.
